RxDoctor Payments Data

Syed Ahmed, MD

Cardiovascular Disease · Flint, MINPI 1023005063

Payments from drug & device makers

$88,565in general payments, 2019–2025

Across 601 payments — averaging $147.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$53K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$13K
  • Novartis$9K
  • Lexicon Pharmaceuticals, Inc.$4K
  • Medtronic$2K
  • Amgen$1K
  • plus $7K from 43 others

What the payments were for

  • Consulting fees$5,62430%
  • Food & beverage$12,91469%
  • Education$1041%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$88,565 in reported general payments places this provider in the 85th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$367,030
Medicare patients
517
Services billed
3,521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan205$254,039
EliquisApixaban186$242,178
XareltoRivaroxaban200$236,603
CamzyosMavacamten23$191,732
JardianceEmpagliflozin100$119,792
FuroscixFurosemide12$72,190
Repatha SureclickEvolocumab56$51,450
BrilintaTicagrelor62$45,782
OzempicSemaglutide39$41,204
VerquvoVericiguat31$40,189
MounjaroTirzepatide18$18,072
NexlizetBempedoic Acid/Ezetimibe18$15,697
Rosuvastatin Calcium542$11,692
KerendiaFinerenone11$10,351
Ranolazine ErRanolazine90$10,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$9,024$254,039205 claims
PfizerEliquis$278$242,178186 claims
Johnson & JohnsonXarelto$356$236,603200 claims
E.r. Squibb & Sons, L.L.C.Camzyos$322$191,73223 claims
Boehringer IngelheimJardiance$545$119,792100 claims
Scpharmaceuticals Inc.Furoscix$229$72,19012 claims
AstraZenecaBrilinta$52,814$45,78262 claims
Novo NordiskOzempic$209$41,20439 claims
MerckVerquvo$489$40,18931 claims
Esperion Therapeutics, Inc.Nexlizet$103$15,69718 claims
BayerKerendia$244$10,35111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →